Clinical trials: Anti-PD-1
Squamous Cell Carcinoma of Anal Canal
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy.
- Trial name
- NCT03597295
- Testing
- Retifanlimab
- Where
- 46 sites in United States, Belgium and 7 more
- Volunteers
- 94 people
- Sponsor
- Incyte Corporation
Advanced NSCLC
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with…
- Trial name
- NSCLC (NCT04043195)
- Testing
- Nivolumab, Oxaliplatin, Ipilimumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hatim Husain
Lung Cancer, Neoplasms
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.
- Trial name
- NCT03360630
- Testing
- Anti-PD-1 plus DC-CIK, Anti-PD-1 alone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Capital Medical University
Advanced Soft-tissue Sarcoma
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
This is a single-arm, multicenter trial of cadonilimab (AK104) with adriamycin in patients with first-line advanced soft tissue sarcoma. the primary objective is to evaluate objective response rate of cadonilimab with adriamycin.
- Trial name
- NCT06367075
- Testing
- Cadonilimab, Adriamycin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cancer
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.
- Trial name
- NCT03351231
- Testing
- BMS-986242, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Extranodal Natural Killer T Cell Lymphoma
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of chidamide, anti-PD1 antibody, and pegaspargase versus dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP) in…
- Trial name
- NCT06255795
- Testing
- chidamide, anti-PD1 antibody, and pegaspargase, DDGP
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Ruijin Hospital
Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
The purpose of this study is to explore the efficacy and safety of SHR-1210 in combination with apatinib in treating patients with metastatic, persistent, or recurrent cervical cancer.
- Trial name
- NCT03816553
- Testing
- SHR-1210, Apatinib
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Healthy Male Adults Participants
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations
This study is to evaluate the pharmacokinetic (PK) similarity of AK104 (an anti-PD-1/CTLA-4 bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male participants.
- Trial name
- NCT07619001
- Testing
- AK104 (New Site), AK104 (Original Site)
- Where
- China
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Akeso
Non Squamous Non Small Cell Lung Cancer
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The objective of this bridging study is to acquire new drug approval in Korea for camrelizumab (SHR-1210), a drug that has already been approved in China for treatment in patients with histologically or cytologically confirmed…
- Trial name
- NCT05841472
- Testing
- Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
- Where
- 8 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- CrystalGenomics, Inc.
Advanced Non-Small Cell Lung Carcinoma
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
The primary objective of the study is to compare the objective response rate (ORR) of high dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy (SDREGN2810/ipi) to the ORR of standard dose…
- Trial name
- NCT03430063
- Testing
- SDREGN2810, SDREGN2810/ipi, HDREGN2810
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 28 people
- Sponsor
- Regeneron Pharmaceuticals
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-paclitaxel in the second-line treatment of patients with advanced…
- Trial name
- NCT07139587
- Testing
- Iparomlimab/Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-bound paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingxia Li
Classical Hodgkin Lymphoma
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL who recently progressed on anti-PD1 therapy.
- Trial name
- AERN (NCT03480334)
- Testing
- Nivolumab plus radiotherapy
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- University of Cologne
Advanced Solid Tumor
Study of AGEN1571 in Participants With Advanced Solid Tumors
This is an open-label, Phase 1, 2-part trial to determine recommended phase 2 doses (RP2Ds) and evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of AGEN1571 both as a monotherapy and in combination…
- Trial name
- NCT05377528
- Testing
- AGEN1571, Balstilimab, Botensilimab
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Agenus Inc.
Colorectal Cancer
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC
This is an open-label, multicenter, phase Ib/II combined trial of sitagliptin, XELOX chemotherapy regimen, and PD-1 monoclonal antibody in the treatment of proficient mismatch repair locally advanced colorectal cancer.
- Trial name
- Neo-CD (NCT07365592)
- Testing
- Oxaliplatin, Capecitabine, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Recurrent Rectal Cancer
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer
The study is a prospective, single-center, single-arm, phase II clinical trial. Patients with pelvic recurrent rectal cancer aged from 18 to 75 years, Eastern Cooperative Oncology Group performance status of 0-1, will receive…
- Trial name
- TRACER (NCT06751394)
- Testing
- PD-1 antibody (Toripalimab), Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Soft Tissue Sarcoma
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma
Chemotherapy is controversial for soft tissue sarcoma that has not yet metastasized. Surgery and radiation are effective for local control, but there are no highly effective interventions to prevent metastatic spread of soft…
- Trial name
- NEXIS (NCT03116529)
- Testing
- Combination Radiation, Immunotherapy, Surgery
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Maryland, Baltimore
Breast Cancer
Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
This is a multi-center, prospective, interventional, single-arm clinical trial. In the study, patients with her2-positive recurrent or metastatic breast cancer who were initially treated were included.
- Trial name
- NCT05291910
- Testing
- Inetetamab, Toripalimab, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese Academy of Medical Sciences
Solid Tumor
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
Phase I/II multicenter, open-label, single-arm trial in patients to evaluate the safety and effect of NECVAX-NEO1 administered in combination with PD-1/PD-L1 mABs in patients with solid tumors.
- Trial name
- NCT06631079
- Testing
- NECVAX-NEO1
- Where
- 8 sites in Germany, Lithuania and 1 more
- Volunteers
- 20 people
- Sponsor
- NEC Bio B.V
Nasopharyngeal Carcinoma (NPC)
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
The main questions it aims to answer are: 1. Does the combination of GP induction chemotherapy and toripalimab improve the 3-year progression-free survival (PFS) compared to GP induction chemotherapy with placebo? 2.
- Trial name
- Navigation (NCT06712888)
- Testing
- TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy
- Where
- 10 sites in China
- Volunteers
- 466 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.